Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:

• Jefferies 2019 London Healthcare Conference
  Date: Wednesday, November 20, 2019
  Presentation Time: 3:20 p.m. GMT
  Location: London

• Piper Jaffray 31st Annual Healthcare Conference
  Date: Tuesday, December 3, 2019
  Presentation Time: 8:00 a.m. EST
  Location: New York

Live webcasts of these presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005714/en/

Charles Liles
626-737-8118
[email protected]

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
[email protected]

Source: Xencor, Inc.

You May Also Be Interested In

• AULUMU Expands the G09 Series with the Transparent G09 Ghost Magnetic Stand
• SOUEAST S08 DM Delivers “Extra-Time Range” for Football Fans’ Journeys
• Best Hellstar Shirt Colorways: Black and Grey Editions Worth Buying